BEIJING, Sept 24 (Reuters) - China's Sinovac Biotech expects to begin analysing final-stage human trial data on its coronavirus vaccine candidate this year to decide whether it is effective enough to ...
Special Meeting validly adjourned until the appropriate court makes a final decision on validity of the PIPE shares and will be reconvened SAIF and the Dissenting Investor Group’s deceptive claims of ...
Highlights bold steps to restore fairness to SINOVAC’s common shareholders and deliver long-term value creation Urges shareholders to VOTE the WHITE proxy card “AGAINST” the misguided proposals to ...
BEIJING, July 19 (Reuters) - Chinese vaccine firm CanSino Biologic's inhalation-based candidate elicited a better antibody response as a booster against the BA.1 Omicron sub-variant than Sinovac's ...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, ...
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel ...
BEIJING, China,--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial ...
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the ...
Chinese vaccine firm CanSino Biologic's inhalation-based candidate elicited a better antibody response as a booster against the BA.1 Omicron sub-variant than Sinovac's shot, but the antibody level ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results